N
Nanjing King-friend Biochemical Pharmaceutical Co Ltd
SSE:603707
Nanjing King-friend Biochemical Pharmaceutical Co Ltd
SSE:603707
Price:
9.84
CNY
-0.1%
Market Cap:
¥15.9B
Relative Value
The Relative Value of one Nanjing King-friend Biochemical Pharmaceutical Co Ltd stock under the Base Case scenario is 10.76 CNY. Compared to the current market price of 9.84 CNY, Nanjing King-friend Biochemical Pharmaceutical Co Ltd is Undervalued by 9%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
Relative Value
Base Case
10.76
CNY
Undervaluation 9%
N
Multiples Across Competitors
Competitors Multiples
Nanjing King-friend Biochemical Pharmaceutical Co Ltd Competitors
Nanjing King-friend Biochemical Pharmaceutical Co Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CN |
N
|
Nanjing King-friend Biochemical Pharmaceutical Co Ltd
SSE:603707
|
15.9B CNY | 4.2 | 24.5 | 20.7 | 20.7 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
867.4B USD | 13.3 | 42 | 28.4 | 30.3 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
571.4B USD | 6.1 | 21.3 | 14.8 | 18.2 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
257.8B CHF | 4.2 | 20 | 11.8 | 13.3 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
220.3B GBP | 5 | 28.9 | 16 | 22.6 | |
| CH |
|
Novartis AG
SIX:NOVN
|
228.9B CHF | 5.2 | 21.1 | 13.1 | 16.8 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
283.3B USD | 4.4 | 15.5 | 9.6 | 11.7 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
240.1B USD | 103.6 | -82.1 | 380.1 | 953.2 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.5 | 10.5 | 7.8 | 9.1 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
155.3B USD | 2.5 | 20 | 7.7 | 10.2 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
119.5B USD | 2.5 | 17 | 7.1 | 8.8 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
